Sugi Predict

Sugi Predict / Compounds / SCHEMBL20135013

SCHEMBL20135013

SCHEMBL20135013

COc1cc(C(=O)O)c(F)cc1C1(C(C)C)NC(=O)NC1=O

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS5 Q9UNA0 13/20 0.35
▸ ADAMTS4 O75173 9/20 0.35
▸ LCK P06239 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ FABP4 P15090 1/20 0.34
▸ ADAM17 P78536 3/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ AKR1A1 P14550 1/20 0.33
▸ AKR1B1 P15121 1/20 0.33
▸ PRKAB2 O43741 1/20 0.33
▸ PRKAG1 P54619 1/20 0.33
▸ PRKAA2 P54646 1/20 0.33
▸ PRKAA1 Q13131 1/20 0.33
▸ PRKAG3 Q9UGI9 1/20 0.33
▸ PRKAG2 Q9UGJ0 1/20 0.33
▸ PRKAB1 Q9Y478 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135280 0.87 LCK (0.35) ADAMTS5ADAMTS4LCKFYNADAM17
SCHEMBL20135032 0.78 CA12 (0.47) LMNAMAPK1HTTRAB9A
SCHEMBL20135629 0.75 AKR1B1 (0.35) ADAMTS5ADAM17AKR1B1
SCHEMBL20135071 0.74 ADAMTS5 (0.38) ADAMTS5ADAMTS4ADAM17
SCHEMBL29688690 0.74 ADAMTS5 (0.38) ADAMTS5ADAMTS4ADAM17
SCHEMBL29688564 0.73 TSHR (0.33) ADAMTS5ADAM17AKR1B1
SCHEMBL20135358 0.73 TSHR (0.33) ADAMTS5ADAM17AKR1B1
SCHEMBL29688586 0.70 KDM4E (0.35) ADAMTS5ADAM17
SCHEMBL20135169 0.70 KDM4E (0.35) ADAMTS5ADAM17
SCHEMBL20135592 0.70 ESRRA (0.34) ADAMTS5ADAM17AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 — — CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ADAMTS5 23/4885ADAMTS4 21/4885LCK 2962/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ADAMTS5 25/4885ADAMTS4 20/4885LCK 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.